While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Q4 2024 Earnings Call Transcript February 12, 2025 Operator: Good morning. My name is Jennifer and I will be your conference ...

At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. (Operator Instructions) Today's conference is being recorded. Thank you. I ...

Q4 2024 Earnings Conference Call February 12, 2025 8:30 AM ETCompany ParticipantsTim Power - Head of IRChris Viehbacher ...

Biogen Inc. (NASDAQ:BIIB) is a global biopharmaceutical company specializing in delivering advanced therapies for patients with complex diseases. Its wide portfolio of medicines addresses ...

Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset ...

Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...

Mitsubishi Chemical Group has agreed to sell its pharmaceutical business to Bain Capital for more than $3 billion, in a bid to focus on its key chemical businesses. The Japanese chemical company said ...

Its best-selling drugs include Radicava for amyotrophic lateral sclerosis, which competes with Biogen's Qalsody. Foreign investment firms like Bain Capital have been riding a growing wave of ...

and generic drug riluzole (sold as Rilutek by Sanofi), and Biogen's Qalsody (tofersen), the latter only if they have a genetic form of ALS associated with a mutation in the SOD1 gene.

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...